SAN

73.15

-0.69%↓

ARGX

758.2

-2.17%↓

SHL.DE

34.3

-0.17%↓

PHIA

23.87

+1.32%↑

FRE

39.77

-0.35%↓

SAN

73.15

-0.69%↓

ARGX

758.2

-2.17%↓

SHL.DE

34.3

-0.17%↓

PHIA

23.87

+1.32%↑

FRE

39.77

-0.35%↓

SAN

73.15

-0.69%↓

ARGX

758.2

-2.17%↓

SHL.DE

34.3

-0.17%↓

PHIA

23.87

+1.32%↑

FRE

39.77

-0.35%↓

SAN

73.15

-0.69%↓

ARGX

758.2

-2.17%↓

SHL.DE

34.3

-0.17%↓

PHIA

23.87

+1.32%↑

FRE

39.77

-0.35%↓

SAN

73.15

-0.69%↓

ARGX

758.2

-2.17%↓

SHL.DE

34.3

-0.17%↓

PHIA

23.87

+1.32%↑

FRE

39.77

-0.35%↓

Search

Almirall SA

Atidarymo kaina

SektoriusSveikatos priežiūra

11.22 0.18

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.1

Max

11.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.3M

15M

Pardavimai

-257M

291M

P/E

Sektoriaus vid.

59.263

50.958

Pelnas, tenkantis vienai akcijai

0.071

Dividendų pajamingumas

1.7

Pelno marža

5.258

Darbuotojai

2,108

EBITDA

135M

237M

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

1.70%

2.41%

Kitas uždarbis

2026-07-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-74M

2.5B

Ankstesnė atidarymo kaina

11.04

Ankstesnė uždarymo kaina

11.22

Naujienos nuotaikos

By Acuity

58%

42%

282 / 342 reitingas Healthcare

Almirall SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Apie bendrovę Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat